Crinetics Pharmaceuticals, Inc.(CRNX)Earnings, Financials & Key RatiosCrinetics Pharmaceuticals, Inc. (CRNX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on non-recurring revenue and an accelerating quarterly cash burn of $125.5M in 2026Q1 present significant binary risks that outweigh current fundamental stability.
Crinetics Pharmaceuticals, Inc. (CRNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Crinetics Pharmaceuticals, Inc. (CRNX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.23vs $1.22-0.8% | $11Mvs $9M+26.1% |
| Q1 2026 | Feb 26, 2026 | $1.29vs $1.37+5.8% | $6Mvs $4M+37.2% |
| Q4 2025 | Nov 6, 2025 | $1.38vs $1.27-8.7% | $143,000vs $4M-96.7% |
| Q3 2025 | Aug 7, 2025 | $1.23vs $1.13-8.8% | $1Mvs $394,000+161.7% |
Recent stock market news and headlines for Crinetics Pharmaceuticals, Inc. (CRNX)
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Crinetics Pharmaceuticals maintains a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for acromegaly. The company advances atumelnant, its oral ACTH receptor antagonist, with promising phase 2 data for CAH and ACTH-dependent Cushing's syndrome. Q1 2026 Palsonify revenues reached $10.3M, beating expectations, but the company's cash runway remains limited to at least 12 months.
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.
Key metrics vs top competitors for Crinetics Pharmaceuticals, Inc. (CRNX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $42.03 | $4.43B | -8.49 | 640.71% | -6046.22% | -40.17% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $1.56 | $190.96M | -1.08 | -84.2% | -323.49% | -174.71% | — | |
| $7.43 | $1.3B | -19.05 | 19.22% | -7.97% | -14.27% | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — | |
| $9.35 | $1.54B | 3.68 | 64.69% | -14.73% | — | — |
Crinetics Pharmaceuticals, Inc. (CRNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Crinetics Pharmaceuticals, Inc. (CRNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Apr 10, 2026·SEC
Mar 23, 2026·SEC
Get notified when CRNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Crinetics Pharmaceuticals, Inc. (CRNX) stock FAQ — growth, dividends, profitability & financials explained
Crinetics Pharmaceuticals, Inc. (CRNX) reported $18.1M in revenue for fiscal year 2025. This represents a 2968% increase from $0.6M in 2016.
Crinetics Pharmaceuticals, Inc. (CRNX) grew revenue by 640.7% over the past year. This is strong growth.
Crinetics Pharmaceuticals, Inc. (CRNX) reported a net loss of $496.4M for fiscal year 2025.
Crinetics Pharmaceuticals, Inc. (CRNX) has a return on equity (ROE) of -40.2%. Negative ROE indicates the company is unprofitable.
Crinetics Pharmaceuticals, Inc. (CRNX) had negative free cash flow of $419.5M in fiscal year 2025, likely due to heavy capital investments.
